PRODUCT DESCRIPTION Salmeterol + Fluticasone propionate (Seretide) 25/50mcg Metered Dose Inhaler: Each single actuation provides salmeterol xinafoate equivalent to 25mcg of salmeterol and 50mcg of fluticasone propionate. Salmeterol + Fluticasone propionate (Seretide) 25/125mcg Metered Dose Inhaler: Each single actuation provides salmeterol xinafoate equivalent to 25mcg of salmeterol and 125mcg ...

then done with either placebo (n 21) or salmeterol 42 g twice daily (n 154) for 2 weeks at stable doses. Next was an ICS reduction phase over the next 8 weeks as all 21 patients on triamcinolone plus placebo were assigned to receive half the dose of triamcinolone 200 g twice daily plus continued placebo (placebo–minus group). Patients on full dose ICS plus salmeterol were randomized to either c...

The efficacy and safety of salmeterol alone was compared with the combination of salmeterol plus ipratropium and with placebo during long-term treatment in patients with stable chronic obstructive pulmonary disease. In addition, the single-dose effect in response to the first dose of treatment was studied over 12 h. The patients (n=144; age 64+/-7 yrs, forced expiratory volume in one second (FE...

STUDY OBJECTIVE To assess whether the withdrawal of salmeterol treatment for 3 days (72 h) can restore its bronchoprotective ability on specific bronchial provocative test (sBPT) with allergen, which was completely lost after 1 week of regular treatment with salmeterol. STUDY DESIGN Single-blind design. PATIENTS AND METHODS We investigated 10 nonsmoking subjects (8 men and 2 women; mean +/-...

Lipopolysaccharide is ubiquitously present in the environment. To determine the effect of salmeterol, a long-acting beta(2)-receptor agonist, on lipopolysaccharide-induced lung inflammation, mice received lipopolysaccharide (10 microg) intranasally with or without salmeterol intraperitoneally (5 mg/kg) 30 min earlier and 12 h thereafter. Salmeterol dose- and time-dependently inhibited the lipop...

BACKGROUND GSK233705 is an inhaled, long-acting muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease (COPD). This study was performed to see if the addition of GSK233705 to salmeterol would provide greater bronchodilation than salmeterol or tiotropium alone in COPD. METHODS In an incomplete-block, three-period, crossover design, dually responsive pat...

Salmeterol is approximately eight times as potent as salbutamol for systemic effects. This may be because the drug is eight times more potent on receptors or there may be differences in systemic bioavailability. The systemic effects of salbutamol are limited by its fairly high first-pass metabolism, but the oral bioavailability of salmeterol is unknown. The contribution of the swallowed fractio...

BACKGROUND The relationship between airway structural changes (remodeling) and airways hyperresponsiveness (AHR) is unclear. Asthma guidelines suggest treating persistent asthma with inhaled corticosteroids and long acting beta-agonists (LABA). We examined the link between physiological function and structural changes following treatment fluticasone and salmeterol separately or in combination i...

Background: Chronic Obstructive Pulmonary Disease (COPD) is one of the four largest types non-communicable diseases in world, requiring long-term and routine treatment. Treatment with inhalation route form a dry-powder inhaler (DPI) which easy to use carry. Combination corticosteroid long-acting beta-2 agonist (LABA) DPI available Indonesia are budesonide/formoterol salmeterol/fluticasone. The ...

Salmeterol/fluticasone propionate (Seretide/Advair Diskus [dry powder inhaler] or Seretide/Advair inhalation aerosol [metered-dose inhaler]) is a fixed-dose combination inhalation agent containing a long-acting beta2-adrenoceptor agonist (LABA) plus a corticosteroid. In patients with symptomatic asthma, twice-daily salmeterol/fluticasone propionate maintenance therapy improves lung function and...